Anti-mu opioid antiserum against the third external loop of the cloned mu-opioid receptor acts as a mu receptor neutral antagonist

Molecular Brain Research

Volumn 119, Issue 1, 2003, Pages 100-110

  Guarna, M ^a   Bartolini, A ^b   Ghelardini, C ^b   Galeotti, N ^b   Bracci, L ^a   Stefano, G B ^c   Bianchi, E ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antibody; Constitutive activity; Mu opioid receptor; Neutral antagonist

Indexed keywords

CHLORNALTREXAMINE; CYCLIC AMP; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIGEN PURIFICATION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHO CELL; CONTROLLED STUDY; DRUG INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIOASSAY; WESTERN BLOTTING;

CRICETINAE; CRICETULUS GRISEUS; ORYCTOLAGUS CUNICULUS;

EID: 0142153436     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molbrainres.2003.08.019     Document Type: Article

References (26)

1. Arvidsson U., Riedel M., Chakrabart S., Lee J.H., Nakano A.H., Dado R.J., Loh H.H., Law P.Y., Wessendorf M.W., Elde R. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J. Neurosci. 15:1995;3328-3341.
2. Burford N.T., Wang D., Sadee W. G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity. Biochem. J. 348:2000;531-537.
3. Chartuvedi K., Shahrestanifar M., Howells R.D. Mu opioid receptor: role for the amino terminus as a determinant of ligand binding affinity. Brain Res. Mol. Brain Res. 76:2000;64-72.
4. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. 48:1991;1991-2003.
5. Costa T., Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 86:1989;7321-7325.
6. De Lean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curve. Am. J. Physiol. 235:1978;97-102.
7. Dietrich G., Gaibelet G., Capeyrou R., Butour J.L., Pontet F., Emorine L.J. Implication of the first and third extracellular loops of the mu-opioid receptor in the formation of the ligand binding site: a study using chimeric mu-opioid/angiotensin receptors. J. Neurochem. 70:1998;2106-2111.
8. Ding Y.Q., Kaneko T., Nomura S., Mizumo P. Immunohistochemical localization of mu opioid receptors in the central nervous system of the rat. J. Comp. Neurol. 367:1996;375-402.
9. Ide S., Sakano K., Seki T., Awamura S., Satoh M. Endomorphin-1 discriminates the mu-opioid receptor from the delta- and kappa-opioid receptors by recognizing the difference in multiple regions. Jpn. J. Pharmacol. 83:2000;306-311.
10. Kitchen I., Slowe S.J., Matthes H.W., Kieffer B. Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res. 778:1997;73-88.
11. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;680-685.
12. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16:1995;89-97.
13. Lefkowitz R.J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14:1993;303-307.
14. Liu J.G., Ruckle M.B., Prather P.L. Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin. J. Biol. Chem. 276:2001;37779-37786.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 193:1951;265-275.
16. Mansour A., Taylor L.P., Fine J.L., Thompson R.C., Hoversten M.T., Mosberg H.I., Watson S.J., Akil H. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J. Neurochem. 68:1997;344-353.
17. Metzger T.G., Ferguson D.M. On the role of extracellular loops of opioid receptors in conferring ligand selectivity. FEBS Lett. 375:1995;1-4.
18. Minami M., Satoh M. Molecular biology of the opioid receptors: structures, functions and distribution. Neurosci. Res. 23:1995;121-145.
19. Monory K., Bourin M.C., Spetea M., Tomboly C., Toth G., Matthes H.W., Kieffer B.L., Hanoune J., Borsodi A. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2. Eur. J. Neurosci. 12:2000;577-584.
20. Pasternak G.W. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol. Sci. 22:2001;67-70.
21. Seki T., Minami M., Nagakawa T., Ienaga Y., Morisada A., Satoh M. DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors. Eur. J. Pharmacol. 350:1998;301-310.
22. Selley D.E., Cao C., Liu Q., Childers R. Effects of sodium on agonist efficacy for G-protein activation in μ-opioid receptor-transfected CHO cells and rat thalamus. Br. J. Pharmacol. 130:2000;987-996.
23. Towbin H., Stehelin T., Gordon S. Electrophoretic transfer of proteins from polyacrilamide gels to nitrocellulose sheets: procedure and some application. Proc. Natl. Acad. Sci. U. S. A. 76:1979;4350-4354.
24. Wang D., Kirten M.R., Bilsky E.J., Sadee W. Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J. Neurochem. 77:1990;1590-1600.
25. Whittaker V.P. Lajtha A. Handbook of Neurochemistry. vol. 2:1965;327-364 Plenum, New York.
26. Xue J.C., Chen C., Zhu J., Kunapuli S.P., Kim de Rief J., Yu L., Liu-Chen L.Y. The third extracellular loop of the mu-opioid receptor is important for agonist selectivity. J. Biol. Chem. 270:1995;12977-12979.